Athersys, Inc. was a big mover last session, as its shares rose a little over 5% on the day. The move came after the company announced that it had received an agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design and planned analysis of a Phase 3 clinical trial of Athersys’ novel MultiStem cell therapy product for the treatment of ischemic stroke. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.91 to $2.02 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Athersys currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

ATHERSYS INC Price

 

ATHERSYS INC Price | ATHERSYS INC Quote

A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN Quick QuoteGERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ATHX going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>